Xelevia, a prescription medication, is intended to support the management of certain chronic inflammatory conditions. It is typically utilized in clinical scenarios where moderate to severe symptoms have not been adequately addressed by initial, standard-of-care therapies.

Treatment with Xelevia is aimed at helping patients manage the disease by seeking to reduce the frequency and severity of flare-ups, which are periods of heightened disease activity that may be significantly debilitating. For many individuals, the primary goal of therapy is to support the ability to maintain daily functions and improve overall quality of life.

The medication’s approved uses include supporting the treatment of conditions such as chronic arthritis, severe dermatitis, and certain systemic inflammatory disorders.

---

QuickFact Block

Quick Fact: Relief for Inflammation-Related Symptoms

Who Can and Cannot Use Xelevia?

Xelevia (Sitagliptin) is officially approved for adults with Type 2 Diabetes Mellitus. Eligibility is strictly governed by regulatory classifications concerning hypersensitivity, age, and organ function.

---

Absolute Non-Eligibility

The medicine is contraindicated for any patient with a history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema. Xelevia is not recommended for the treatment of Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (DKA), as its use is not established for these conditions.

---

Conditional Use and Restrictions

Use in patients with moderate or severe renal impairment or End-Stage Renal Disease (ESRD) is conditional, requiring an adjustment of the dose based on the degree of kidney function. Regulatory labels advise caution for patients with a history of pancreatitis and for those with risk factors for heart failure.

---

Age and Reproductive Status

The safety and effectiveness of Xelevia have not been established for pediatric patients under 18 years of age. Furthermore, use during pregnancy or breastfeeding is not recommended due to a lack of sufficient human data.

Interactions with other medicines and products

The official regulatory profile for Sitagliptin (Xelevia) details specific interaction patterns that mandate restrictions or monitoring. Co-administration with insulin or an insulin secretagogue such as a sulfonylurea creates an additive pharmacodynamic effect, resulting in an increased risk of hypoglycemia. The regulatory restriction for this combination is that a lower dose of the co-administered insulin or sulfonylurea may be required to mitigate this risk.

Pharmacokinetic interactions are primarily defined by effects on drug transporters. Ciclosporin, a potent P-glycoprotein (P-gp) inhibitor, increases Sitagliptin plasma exposure (AUC and Cmax). However, official regulatory labeling classifies this change as not clinically meaningful, concluding that no dose adjustment for Sitagliptin is necessary. Conversely, Sitagliptin is a mild P-gp inhibitor, causing a minor increase in the exposure of Digoxin. For patients at risk of digoxin toxicity, the official requirement is for monitoring to be conducted when the medicines are co-administered.

Sitagliptin is a weak substrate of CYP3A4/CYP2C8. Regulatory documents note that the interaction with potent CYP3A4 inhibitors is of specific consideration for patients with severe renal impairment or End-Stage Renal Disease (ESRD). Sitagliptin may be administered with or without food, as no formal drug-food interaction is documented.

How Xelevia Works: Mechanism of Action

Preserving Incretin Hormones via DPP-4 Inhibition

Xelevia (Sitagliptin) exerts its effect by targeting the Dipeptidyl Peptidase-4 (DPP-4) enzyme, acting as a selective and reversible inhibitor. This action prevents the rapid breakdown and inactivation of the naturally occurring gut hormones, Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP). The key physiological result is the sustained elevation of active incretin hormone concentrations in the circulation, which constitutes the entire entero-pancreatic feedback loop.

---

Coordinating Pancreatic and Hepatic Glucose Control

The preserved incretins facilitate a dual, glucose-dependent regulatory effect on the pancreas and liver. This enhanced signaling boosts the secretion of insulin from beta-cells only when blood glucose levels are high, while simultaneously suppressing the release of counter-regulatory glucagon from alpha-cells. This coordinated control reduces the output of glucose from the liver (Hepatic Glucose Production) and facilitates the physiological processes governing the uptake and utilization of circulating glucose.

How to Use Xelevia

Xelevia (sitagliptin) is an antidiabetic medicine administered via the oral route as a film-coated tablet. Its usage follows specific guidelines focusing strictly on administration patterns rather than therapeutic outcomes or safety.

---

Official Administration Guidelines

Instruction	Detail
Route of Administration	Oral administration as a film-coated tablet.
Dosing Schedule	The standard dose for adults with normal renal function is 100 mg once daily.
Frequency and Timing	The tablet is taken once daily (QD) and may be administered with or without food.
Missed Dose Rules	If a dose is missed, it should be taken as soon as it is remembered. Patients are instructed not to take more than one dose on the same day to make up for a missed dose.

---

Population-Specific Use

Strict dose adjustments are required based on renal function status. For patients with moderate renal impairment, the recommended dose is lowered to 50 mg once daily. For severe renal impairment (eGFR < 30 mL/min/1.73 m^2) or End-Stage Renal Disease (ESRD) requiring dialysis, the dose is 25 mg once daily. This requirement means renal function assessment is necessary before starting and periodically during treatment. The 25 mg dose for ESRD patients is administered without regard to the timing of dialysis.

---

Treatment Structure

Xelevia is intended for long-term chronic management as part of a comprehensive therapeutic plan for Type 2 diabetes mellitus. The protocol defines a clear, once-daily framework, with the main procedural variable being the mandatory dose modification tied directly to the patient’s level of kidney function.

Research evidence / Overview of studies

Evidence for Primary Indication (Type 2 Diabetes)

Studies have explored the theoretical mechanism of action, which involves investigating the expression of key inflammatory markers related to the dipeptidyl peptidase-4 (DPP-4) enzyme. This investigation was conducted using both in vitro and animal models.

Phase 3 Randomized Controlled Trials (RCTs)

A primary body of evidence for its effect on blood sugar comes from large Phase 3 randomized controlled trials. These studies evaluated whether the use of the drug was associated with changes in glycated hemoglobin (HbA1c), a key marker of long-term blood glucose control. In monotherapy studies, participants experienced reductions in HbA1c levels compared to those taking placebo.

Combined therapy trials examined the drug's effect when added to other existing treatments, such as metformin or a sulfonylurea, noting additional changes in HbA1c levels.

Cardiovascular Safety Profile

The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) was a large-scale, long-term study specifically designed to assess cardiovascular safety. This trial evaluated the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease.

• TECOS Conclusion: The study demonstrated that the use of this drug did not increase the risk of the primary composite cardiovascular outcome (which includes cardiovascular-related death, nonfatal stroke, nonfatal myocardial infarction, or hospitalization for unstable angina) when compared to placebo.
• Heart Failure: Rates of hospitalization for heart failure were similar between the group receiving the drug and the group receiving placebo.

Researchers explored the tolerability and observed side effects of the therapy. Post-marketing reports have included rare cases of acute pancreatitis and hypersensitivity reactions.

Common questions about Xelevia (FAQ)

Q: Is it normal to feel nauseous when starting Xelevia?

According to official product information, nausea and vomiting are documented side effects. These gastrointestinal effects are listed as common when Xelevia is used alongside the medication metformin. This information indicates that such feelings are documented and may be experienced while using the medicine.

---

Q: What is the shelf life of Xelevia tablets?

Official documents state the medicine should not be used after the expiration date printed on the packaging. Additionally, for specific packaging types, such as the HDPE container, the shelf life after the container is first opened is limited to one month.

---

Q: Does Xelevia need to be taken at a specific time of day?

Official labeling states that Xelevia is intended to be taken once daily. The regulatory information does not mandate a specific time (such as morning or night) for administration.

---

Q: Can Xelevia be used by older adults (e.g., over 65)?

Xelevia is indicated for use in adults with Type 2 diabetes. Studies examined the medicine's use in patients aged 65 and over and found no overall differences in safety or effectiveness compared to younger adult patients.

---

Q: Does Xelevia cause stomach upset?

When used as part of a combination therapy, such as with metformin, official documents list gastrointestinal issues as common side effects. These effects can include nausea, flatulence, and vomiting.

---

Q: How is Xelevia removed from the body?

Official product information describes the drug's path of removal from the body. Sitagliptin, the active ingredient, is primarily eliminated through the kidneys. This renal (kidney) excretion pathway is why specific dose adjustments are required for patients with impaired kidney function.

---

Q: Are headaches a common initial side effect of Xelevia?

Headache is listed in the official documents as one of the most commonly reported adverse reactions during clinical trials. The fact that headache is a common reaction means it is reported frequently.

---

Q: Is Xelevia considered a blood pressure medicine?

Xelevia is pharmacologically classified as a Dipeptidyl Peptidase-4 (DPP-4) inhibitor. Its primary indication, according to regulatory labels, is to improve glycemic control (blood sugar) in adults with Type 2 diabetes. It is not indicated for the treatment of high blood pressure.

---

Q: Does Xelevia cause weight gain or loss?

The clinical profile of sitagliptin has been examined against other diabetes treatments. Studies have shown that when compared to certain other medications in this class, sitagliptin was associated with lower rates of weight gain.

---

Q: Is fatigue a common side effect reported for Xelevia?

Official warnings advise patients to monitor for symptoms such as unusual tiredness. This is noted because fatigue is listed as a symptom that patients should monitor, as it may be a sign of a more serious condition such as heart failure, which is a warning listed in the product information.

---

Q: Can you drink alcohol while taking Xelevia?

Official drug guides confirm that patients can generally consume alcohol with sitagliptin. However, regulatory information suggests limiting consumption because alcohol can increase the risk of developing low blood sugar (hypoglycaemia), especially when combined with a diabetes medication.

---

Q: Can Xelevia cause dry mouth?

Dry mouth is listed in the official adverse reaction reports. According to these regulatory documents, it is classified as an uncommon side effect, particularly when Xelevia is used as part of a combination regimen with insulin.

---

Q: Can Xelevia be split or crushed?

Regulatory constraints regarding swallowing tablets whole have been adjusted. Patients should always refer to the specific usage instructions provided by their doctor or pharmacist for their prescribed tablet form.

---

Q: What should be done if someone accidentally takes too much Xelevia?

Official documents state that in the event of excessive intake, general supportive measures are typically provided. The active ingredient, sitagliptin, can be removed from the bloodstream using hemodialysis, although only a small amount is generally cleared this way.

---

Q: Is Xelevia a controlled substance?

No. According to the specific sections of the US Food and Drug Administration (FDA) label that classify medicines for potential abuse, sitagliptin is not designated as a controlled substance.

---

Q: Does Xelevia have a warning about driving or operating machinery?

Regulatory information notes the potential for the uncommon side effect of dizziness. Furthermore, patients should be aware of the risk of low blood sugar (hypoglycaemia) when used with other diabetes medicines, as this may affect their ability to drive or safely use machinery.

How to Store and Dispose of Xelevia (Sitagliptin)

Official regulatory labeling dictates strict storage and disposal requirements for Xelevia tablets to ensure stability and safety.

---

Storage Requirements

Condition	Requirement
Temperature	Store below 25°C (77°F).
Protection	Keep away from excess heat, moisture, and direct light. Protect from freezing.
Packaging	Store in the original container, tightly closed, and keep tablets in the blister pack until use.
Child Safety	Keep out of the sight and reach of children.

---

Disposal Instructions

Do not use the medicine past its labeled expiry date.

For disposal, do not throw Xelevia away via household trash or wastewater.

Unused or expired product must be disposed of safely by consulting a pharmacist or local waste authority about proper pharmaceutical collection programs.